Spherical Crystallization for Lean Solid-Dose Manufacturing (Part 1) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Spherical Crystallization for Lean Solid-Dose Manufacturing (Part 1)
In Part I of this article, the authors describe the materials and methods used in developing a screening strategy to accelerate the preparation and characterization of spherical agglomerates by spherical crystallization.


Pharmaceutical Technology
Volume 34, Issue 3, pp. 72-75

22. Y. Kawashima et al., Powder Technol. 130 (1), 283–289 (2003).

23. A.P. Pawar et al., AAPS PharmSciTech. 5 (3), Article 44 (2004).

24. S. Bhadra et al., Pharm. Technol. 28 (2), 66–76 (2004).

25. M. Maghsoodi et al., Drug Dev. Ind. Pharm. 33 (11), 1216–1224 (2007).

26. J. Katta and A.C. Rasmuson, Int. J. Pharm. 348 (1–2), 61–69 (2008).

27. T. Lee, C.S. Kuo, and Y.H. Chen, Pharm. Technol. 30 (10), 72–92 (2006).

28. T. Lee, Y. H. Chen and C.W. Zhang, Pharm. Technol. 31 (6), 72–87 (2007).

29. T. Lee and M.S. Lin, Cryst. Growth and Design 7 (9), 1803–1810 (2007).

30. T. Lee et al., Pharm. Technol. 33 (6), 54-61 (2009).

31. J. Alsenz and M. Kansy, Adv. Drug Deliv. Rev. 59 (7), 546–567 (2007).

32. L.E. McMahon et al., J. Pharm. Sci. 85 (10), 1064–1069 (1996).

33. A.L. Grzesiak et al., J. Pharm. Sci. 92 (11), 2260–2271 (2003).

34. N. Rodríguez-Hornedo and D. Murphy, J. Pharm. Sci. 93 (2), 449–460 (2004).

35. F. Tian et al., J. Pharm. Sci. 96 (3), 584–594 (2007).

36. B. Hegedüs and S. Görög, J. Pharm. Biomed. Analysis 3 (4), 303–313 (1985).

37. S. Sudo, K. Sato, and Y. Harano, J. Chem. Eng. Japan 24 (2), 237–242 (1991).

38. A. M. Tudor et al., Spectrochimica Acta, 47A (9–10), 1389–1393 (1991).

39. A. Bauer-Brandl, Intl. J. Pharm. 140 (2), 195–206 (1996).

40. W.A. Bueno and E.G. Sobrinho, Spectrochimica Acta 51A (2), 287–292 (1995).

41. M.D. Tuladhar, J.E. Carless, and M.P. Summers, J. Pharm. Pharmacol. 35 (4), 208–214 (1983).

42. T. Hosokawa et al., Cryst. Eng. Comm. 6 (44), 243–249 (2004).

Note

The results and related discussion will be included in Part II of this article, which appear in the April 2010 issue of Pharmceutical Technology.

Note

For a detailed review of approaches in initial solvent screening, see Part I and Part II of the article, "Initial Solvent Screening of Carbamazepine, Cimetidine, and Phenylbutazone," which respectively appeared in the May and April 2009 issues of Pharmaceutical Technology.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here